title: Dermatologic findings in renal transplant recipients: Possible effects of immunosuppression regimen and p53 mutations.
abstract: OBJECTIVE
  To analyze the dermatologic lesions and possible effects of immunosuppression treatment and p53 gene mutations on dermatologic findings in renal transplant recipients.
  
  
  METHODS
  The study included 163 renal transplant recipients. After dermatologic examination, cultures, and histopathologic and genetic analyses were performed. A single-strand conformation polymorphism technique was used to analyze p53 gene mutations. Patients were categorized into 3 groups according to time since the transplantation procedure. Results were analyzed using the χ(2) test, using a software program (SPSS version 13.0; SPSS, Inc, Chicago, Illinois).
  
  
  RESULTS
  Mean (SD) age of the 163 transplant recipients (65 women and 98 men) was 40 (11) years, and posttransplantation follow-up was 65 (55) months. The most frequently observed drug-related lesion was hypertrichosis, in 46 of 150 patients. Of 115 lesions, the most commonly observed were verruca vulgaris (n = 34) from viruses, and pityriasis versicolor (n = 21) from superficial fungal infections. Of the total group, 20 patients (12.2%) were mutation carriers. Compared with the entire cohort, the group with premalignant lesions demonstrated more p53 mutations (11% vs 50%; P = .004). Patients given cyclosporine therapy exhibited more premalignant or malignant cutaneous lesions compared with patients who received other agents (P = .03).
  
  
  CONCLUSIONS
  Patients carrying p53 mutations developed a malignant lesion in the late posttransplantation period, which suggests the importance of prediction of risk.
authors.affiliation: Department of Dermatology Haydarpasa Numune Research and Training Hospital Istanbul, Turkey. drzehraserdar@yahoo.com
authors.forename: Z A
authors.initials: ZA
authors.lastname: Serdar
authors.forename: P A
authors.initials: PA
authors.lastname: Eren
authors.forename: M
authors.initials: M
authors.lastname: Canbakan
authors.forename: K
authors.initials: K
authors.lastname: Turan
authors.forename: G
authors.initials: G
authors.lastname: Tellioglu
authors.forename: S
authors.initials: S
authors.lastname: Gülle
authors.forename: T
authors.initials: T
authors.lastname: Ozgezer
authors.forename: M
authors.initials: M
authors.lastname: Kara
authors.forename: I
authors.initials: I
authors.lastname: Berber
authors.forename: M I
authors.initials: MI
authors.lastname: Titiz
mesh_terms: D000328:Adult; D003881:Dermatomycoses / Q000453:epidemiology; D004359:Drug Therapy, Combination; D005091:Exons / Q000235:genetics; D005260:Female; D005500:Follow-Up Studies; D016158:Genes, p53; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D009154:Mutation; D018807:Polymorphism, Single-Stranded Conformational; D011183:Postoperative Complications / Q000235:genetics; D011230:Precancerous Conditions / Q000235:genetics; D017192:Skin Diseases, Bacterial / Q000453:epidemiology; D017193:Skin Diseases, Viral / Q000453:epidemiology; D012878:Skin Neoplasms / Q000235:genetics*; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents